Citations

Showing 10 of 108152 citations.

Sudden Death in the Young: Information for the Primary Care Provider
Erickson, Christopher C. , Salerno, Jack C., Berger, Stuart, Campbell, Robert M. , Cannon, Bryan C. , Christiansen, James L., Pflaumer, Andreas , Snyder, Christopher S. , Srinivasan, Chandra , Valdés, Santiago O. , Vetter, Victoria L. , Zimmerman, Frank, Cannon, Bryan, Christiansen, James, Moffatt, Kody A.

Mayo Clinic

Pediatrics | June 21, 2021 | Volume: 148 | Issue: 1 | Pages: No page available

10.1542/peds.2021-052044 | PMID 34155130 Get It

There are multiple conditions that can make children prone to having a sudden cardiac arrest (SCA) or sudden cardiac death (SCD). Efforts have been made by multiple organizations to screen children for cardiac conditions, but the emphasis has been on screening before athletic competition. This article is an update of the previous American Academy of Pediatrics policy statement of 2012 that addresses prevention of SCA and SCD. This update includes a comprehensive review of conditions that should prompt more attention and cardiology evaluation. The role of the primary care provider is of paramount importance in the evaluation of children, particularly as they enter middle school or junior high. There is discussion about whether screening should find any cardiac condition or just those that are associated with SCA and SCD. This update reviews the 4 main screening questions that are recommended, not just for athletes, but for all children. There is also discussion about how to handle post-SCA and SCD situations as well as discussion about genetic testing. It is the goal of this policy statement update to provide the primary care provider more assistance in how to screen for life-threatening conditions, regardless of athletic status.
Impact of Simulation-Based Training in Dermatologic Surgery and Sharps Safety During Orientation for Dermatology Residents
Kobic, Ajdin, Vidal, Nahid Y.

Mayo Clinic

Dermatologic Surgery | June 21, 2021 | Volume: 47 | Issue: 9 | Pages: 1292-1292

10.1097/dss.0000000000003127 | PMID 34148995 Get It

Predictors of angina resolution after percutaneous coronary intervention in stable coronary artery disease
Verreault-Julien, Louis, Bhatt, Deepak L., Jung, Richard G., Santo, Pietro Di, Simard, Trevor, Avram, Robert, Hibbert, Benjamin, Bhatt, Deepak L. , Avram, Robert , Hibbert, Benjamin , Verreault‐Julien, Louis , Bhatt, Deepak L , Hibbert, Benjamin , Bhatt, Deepak L., Jung, Richard G., Santo, Pietro Di, Simard, Trevor

Mayo Clinic

Coronary Artery Disease | June 21, 2021 | Volume: 33 | Issue: 2 | Pages: 98-104

10.1097/mca.0000000000001081 | PMID 34148973 Get It

Background Elective percutaneous coronary intervention (PCI) is performed to relieve symptoms of angina. Identifying patients who will benefit symptomatically after PCI would be clinically advantageous but robust predictors of symptom resolution are ill-defined. Methods Prospective indexing of baseline angina status, clinical, and procedural characteristics were collected over a 5-year period in a regional revascularization registry. At 1-year follow-up, angina resolution was assessed. We performed a stepwise selection algorithm to identify predictors of persistent angina at 1 year. Results A total of 777 patients were included in the analysis and the median follow-up was 387 days. Mean age of the cohort was 66.6 years, 23.8% were female and 23.3% had baseline Canadian Cardiovascular Society class 3 or 4 angina. Overall, 13.1% had persistent angina. The only predictor of persistent angina was the presence of a residual chronic total occlusion after PCI with odds ratio of 3.06 (95% confidence interval, 1.81–5.17). Residual stenoses 50–69%, 70–89%, and 90–99% were not associated with residual angina after PCI. Conclusion Most patients achieved symptom resolution with PCI and optimal medical therapy. A residual chronic total occlusion after PCI was associated with persistent angina. Other degrees of stenoses were not associated with persistent angina.
An international, randomized, placebo‐controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY‐DLB)
Lang, Frederick , Kwon, Daniel Y. , Aarsland, Dag , Tousi, Babak , Harnett, Mark , Aarsland, Dag , Boeve, Bradley F. , Yi, Mo , Sabbagh, Marwan Noel

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | June 20, 2021 | Volume: 7 | Issue: 1 | Pages: No page available

10.1002/trc2.12171 | PMID 34189249 Get It

Abstract Introduction A phase 2b clinical trial, HEADWAY‐DLB, was performed to assess treatment with intepirdine, a serotonin receptor antagonist, in patients with dementia with Lewy bodies (DLB). Methods HEADWAY‐DLB was a multinational, double‐blind, randomized, placebo‐controlled study. Two hundred sixty‐nine DLB patients were randomized to receive placebo, 70 mg/day intepirdine, or 35 mg/day intepirdine over 24 weeks. The primary endpoint was change from baseline to week 24 on the Unified Parkinson's Disease Rating Scale–Part III (UPDRS‐III). Results Both intepirdine groups did not demonstrate significant benefits over placebo at 24 weeks on the UPDRS‐III (35 mg/day: P = .1580, 70 mg/day: P = .6069). All other endpoints were not significant. Intepirdine was well tolerated, with a slightly higher incidence of gastrointestinal adverse events observed in the intepirdine groups versus placebo. Discussion Intepirdine treatment did not lead to improvements over placebo in patients with DLB. As one of the largest DLB studies to date, HEADWAY‐DLB demonstrates that international trials for DLB are feasible within a reasonable timeframe.
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance)
Patel, Jai N., Jiang, Chen, Owzar, Kouros, Mulkey, Flora, Luzum, Jasmine A., Mamon, Harvey J., Haller, Daniel G., Dragovich, Tomislav, Alberts, Steven R., Bjarnason, Georg, Willet, Christopher G., Niedzwiecki, Donna, Enzinger, Peter, Ratain, Mark J., Fuchs, Charles, McLeod, Howard L., Niedzwiecki, Donna , Owzar, Kouros , Luzum, Jasmine A. , Niedzwiecki, Donna , Luzum, Jasmine A , Patel, Jai N., Jiang, Chen, Mulkey, Flora, Mamon, Harvey J., Haller, Daniel G., Dragovich, Tomislav, Alberts, Steven R., Bjarnason, Georg, Willet, Christopher G., Enzinger, Peter, Ratain, Mark J., Fuchs, Charles, McLeod, Howard L.

Mayo Clinic

Pharmacogenetics and Genomics | June 20, 2021 | Volume: 31 | Issue: 9 | Pages: 215-220

10.1097/fpc.0000000000000442 | PMID 34149004 Get It

There is a lack of pharmacogenetic predictors of outcome in gastric cancer patients. The aim of this study was to assess previously identified candidate genes associated with 5-fluorouracil (5-FU), cisplatin, or epirubicin toxicity or response in a cohort of resected gastric cancer patients treated on CALGB (Alliance) 80101. Gastric or gastroesophageal cancer patients randomized to adjuvant 5-FU/leucovorin or epirubicin/cisplatin/5-FU before and after 5-FU chemoradiation were genotyped for single nucleotide polymorphisms (SNPs) in GSTP1 (rs1695), ERCC1 (rs11615 and rs3212986), XRCC1 (rs25487), UGT2B7 (rs7439366) and the 28 base-pair tandem repeats in TYMS (rs34743033). Logistic regression and log rank tests were used to assess the association between each SNP and incidence of grade 3/4 neutropenia and leukopenia, overall (OS) and progression-free survival (PFS), respectively. Toxicity endpoint analyses were adjusted for the treatment arm, while OS and PFS were also adjusted for performance status, sex, age, lymph node involvement, and primary tumor site and size. Of 281 subjects with successful genotyping results and available clinical (toxicity and efficacy) data, 166 self-reported non-Hispanic White patients were included in the final analysis. There was a lack of evidence of an association among any SNPs tested with grade 3/4 neutropenia and leukopenia or OS and PFS. Age, lymph node involvement, and primary tumor size were significantly associated with OS and PFS. This study failed to confirm results of previous gastric cancer pharmacogenetic studies.
Growing use of home enteral nutrition: a great tool in nutrition practice toolbox
Elfadil, Osman Mohamed , Ewy, Matthew W. , Patel, Jalpan , Patel, Ishani , Ewy, Matthew, Mohamed Elfadil, Osman , Mundi, Manpreet S.

Mayo Clinic

Current Opinion in Clinical Nutrition & Metabolic Care | June 20, 2021 | Volume: 24 | Issue: 5 | Pages: 446-452

10.1097/mco.0000000000000777 | PMID 34148970 Get It

Purpose of review Home enteral nutrition (HEN) is a well-established practical nutrition therapy tool that is typically managed by an interdisciplinary team. Prevalence of HEN is increasing across the globe given significant evidence for utility, feasibility, efficacy, safety, and reliability of HEN in helping patients meeting their nutrition needs. The current review highlights the growing use of HEN in the context of what is novel in the field including trends in HEN practice with regards to tubes and connectors, feeding formula and real food blends, and common complications. The review also highlights that the use of HEN is expected to expand further over coming years emphasizing the need for national consensus recommendations and guidelines for HEN management. Recent findings The growing use of HEN has always been parallel to adoption of holistic definitions and concept of malnutrition in clinical nutrition practice and more understanding of the need for malnutrition risk stratification, meeting unmet needs in practice and addressing challenges that lead to suboptimal enteral nutrition. Summary Research and advancements in technology as well as in tube feeding formula industry have led to the development of more solutions and have helped identify and implement best HEN practices.
Lamin A/C Is Dispensable to Mechanical Repression of Adipogenesis
Goelzer, Matthew , Dudakovic, Amel , Olcum, Melis , Sen, Buer , Özçivici, Engin , Rubin, Janet , Wijnen, André J. van , Uzer, Gunes , van Wijnen, Andre J , Dudakovic, Amel

Mayo Clinic

International Journal of Molecular Sciences | June 20, 2021 | Volume: 22 | Issue: 12 | Pages: 6580

10.3390/ijms22126580 | PMID 34205295 Get It

Mesenchymal stem cells (MSCs) maintain the musculoskeletal system by differentiating into multiple lineages, including osteoblasts and adipocytes. Mechanical signals, including strain and low-intensity vibration (LIV), are important regulators of MSC differentiation via control exerted through the cell structure. Lamin A/C is a protein vital to the nuclear architecture that supports chromatin organization and differentiation and contributes to the mechanical integrity of the nucleus. We investigated whether lamin A/C and mechanoresponsiveness are functionally coupled during adipogenesis in MSCs. siRNA depletion of lamin A/C increased the nuclear area, height, and volume and decreased the circularity and stiffness. Lamin A/C depletion significantly decreased markers of adipogenesis (adiponectin, cellular lipid content) as did LIV treatment despite depletion of lamin A/C. Phosphorylation of focal adhesions in response to mechanical challenge was also preserved during loss of lamin A/C. RNA-seq showed no major adipogenic transcriptome changes resulting from LIV treatment, suggesting that LIV regulation of adipogenesis may not occur at the transcriptional level. We observed that during both lamin A/C depletion and LIV, interferon signaling was downregulated, suggesting potentially shared regulatory mechanism elements that could regulate protein translation. We conclude that the mechanoregulation of adipogenesis and the mechanical activation of focal adhesions function independently from those of lamin A/C.
Addressing intraarticular pathology at the time of anteverting periacetabular osteotomy for acetabular retroversion is associated with better short-term patient-reported outcomes
Panos, Joseph A. , Gutierrez, Claudia N. , Trousdale, Robert T. , Wyles, Cody C. , Bingham, Joshua S. , Mara, Kristin C. , Sierra, Rafael J.

Mayo Clinic

Journal of Hip Preservation Surgery | June 20, 2021 | Volume: 8 | Issue: 1 | Pages: 90-104

10.1093/jhps/hnab040 | PMID 34676101 Get It

AbstractPeriacetabular osteotomy (PAO) is effective in the management of developmental dysplasia of the hip and femoroacetabular impingement secondary to acetabular retroversion. During anteverting PAO for acetabular retroversion, the need for both labral treatment and femoral head–neck junction osteochondroplasty remains equivocal. Accordingly, this study evaluated patient-reported outcome measures (PROM) and reoperation rates after anteverting PAO with or without intraarticular intervention. Cases of anteverting PAO performed at a single institution between November 2009 and January 2016 were retrospectively reviewed. Patients were divided into three groups: no intervention and intraarticular intervention with arthrotomy or arthroscopy. Subsequently, patients were reclassified by the intraarticular procedure performed at surgery into major (labral repair, femoral head–neck osteochondroplasty) and minor (labral debridement, femoral/acetabular chondroplasty) groups. The cohort was 75% female, median age was 19.5 years and mean body mass index was 25.0 kg/m2. Preoperative to postoperative improvement was compared to minimal clinically important differences (MCID) for eight PROM. Patients receiving major interventions exceeded MCID in a greater proportion of PROM compared to minor and no intervention groups (P < 0.007); major or minor interventions did not increase the risk of reoperation over no intervention (P ≥ 0.39). Based on the current data, surgeons performing anteverting PAO for acetabular retroversion should perform arthroscopic or open labral repair and assess for impingement after the correction and perform a head–neck junction osteochondroplasty if indicated.
Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK‐906), a dopamine D2/D3 receptor antagonist, in patients with gastroparesis
Scimia, Cecilia, Dukes, George E. , Zhang, Wenwen , Gupta, Saurabh , Chen, Chunlin , Chuang, Emil , Camilleri, Michael , Camilleri, M , Kuo, Braden

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 20, 2021 | Volume: 54 | Issue: 3 | Pages: 267-280

10.1111/apt.16451 | PMID 34148244 Get It

SummaryBackgroundGastroparesis is a chronic gastric motility disorder. Dopamine D2/D3 receptor antagonists metoclopramide and domperidone are current treatment options but are associated with central nervous system and cardiovascular safety concerns, respectively, precluding chronic use. Trazpiroben (TAK‐906), a dopamine D2/D3 receptor antagonist, is under development for chronic treatment of moderate‐to‐severe gastroparesis. Nonclinical data suggest trazpiroben will have D2/D3 receptor antagonism comparable with metoclopramide or domperidone.AimsTo evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics (effect on prolactin and gastric function) of twice‐daily trazpiroben (5, 25 and 100 mg) in participants with gastroparesis.MethodsThis phase 2a pilot study evaluated gastric emptying using the gastric emptying breath test, with metoclopramide as an internal control. Gastric accommodation and gastroparesis symptoms were assessed using the nutrient drink test and American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index‐Daily Diary, respectively.ResultsOverall, 51 participants were enrolled. Trazpiroben was well tolerated, demonstrating a favourable safety profile without cardiovascular or central nervous system adverse events. All trazpiroben doses were rapidly absorbed and eliminated (t1/2z 4‐5 hours), and D2/D3 receptor target engagement confirmed by increased serum prolactin (peaking at trazpiroben 25 mg). No effect on gastric emptying was demonstrated with trazpiroben or metoclopramide (P > 0.05), although benefits in volume‐to‐fullness were seen at trazpiroben 5 mg (P > 0.05) and 25 mg (88.5 vs −26.3 mL; P = 0.019), and nonsignificant numerical aggregate symptom score improvements were observed with trazpiroben 25 mg vs placebo (P = 0.182).ConclusionsTrazpiroben was well tolerated with a favourable safety profile, supporting its further development for the treatment of gastroparesis. ClinicalTrials.gov identifier: NCT03268941.